IL-6 pathway inhibition has been explored in treating PC from colorectal cancer (CRC) [157], largely as a result of the repeated demonstration that the downstream JAK/STAT3 signaling plays a central role in CRC progression by causing downstream overexpression of VEGF-A and matrix metalloproteinase A (MMP2) [157, 200]. This evidence concerns the gene STAT3 and colorectal carcinoma.